Post-mortem determination of insulin using chemiluminescence enzyme immunoassay: preliminary results.

Insulin determination in blood sampled during post-mortem investigation has been repeatedly asserted as being of little diagnostic value due to the rapid occurrence of decompositional changes and blood haemolysis. In this study, we assessed the feasibility of insulin determination in post-mortem serum, vitreous humour, bile, and cerebrospinal and pericardial fluids in one case of fatal insulin self-administration and a series of 40 control cases (diabetics and non-diabetics) using a chemiluminescence enzyme immunoassay. In the case of suicide by insulin self-administration, insulin concentrations in pericardial fluid and bile were higher than blood clinical reference values, though lower than post-mortem serum concentration. Insulin concentrations in vitreous (11.50 mU/L) and cerebrospinal fluid (17.30 mU/L) were lower than blood clinical reference values. Vitreous insulin concentrations in non-diabetic control cases were lower than the estimated detection limit of the method. These preliminary results tend to confirm the usefulness of insulin determination in vitreous humour in situations of suspected fatal insulin administration. Additional findings pertaining to insulin determination in bile, pericardial, and cerebrospinal fluid would suggest that analysis performed in post-mortem serum and injection sites could be complemented, in individual cases, by investigations carried out in alternative biological fluids. Lastly, these results would indicate that analysis with chemiluminescence enzyme immunoassay may provide suitable data, similar to analysis with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and immunoradiometric assay, to support the hypothesis of insulin overdose. Copyright © 2015 John Wiley & Sons, Ltd.

The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.

The GH-2000 and GH-2004 projects have developed a method for detecting GH misuse based on measuring insulin-like growth factor-I (IGF-I) and the amino-terminal pro-peptide of type III collagen (P-III-NP). The objectives were to analyze more samples from elite athletes to improve the reliability of the decision limit estimates, to evaluate whether the existing decision limits needed revision, and to validate further non-radioisotopic assays for these markers. The study included 998 male and 931 female elite athletes. Blood samples were collected according to World Anti-Doping Agency (WADA) guidelines at various sporting events including the 2011 International Association of Athletics Federations (IAAF) World Athletics Championships in Daegu, South Korea. IGF-I was measured by the Immunotech A15729 IGF-I IRMA, the Immunodiagnostic Systems iSYS IGF-I assay and a recently developed mass spectrometry (LC-MS/MS) method. P-III-NP was measured by the Cisbio RIA-gnost P-III-P, Orion UniQ? PIIINP RIA and Siemens ADVIA Centaur P-III-NP assays. The GH-2000 score decision limits were developed using existing statistical techniques. Decision limits were determined using a specificity of 99.99% and an allowance for uncertainty because of the finite sample size. The revised Immunotech IGF-I - Orion P-III-NP assay combination decision limit did not change significantly following the addition of the new samples. The new decision limits are applied to currently available non-radioisotopic assays to measure IGF-I and P-III-NP in elite athletes, which should allow wider flexibility to implement the GH-2000 marker test for GH misuse while providing some resilience against manufacturer withdrawal or change of assays. Copyright © 2015 John Wiley & Sons, Ltd.

Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis.

Recent studies suggest that M. tuberculosis lineage and host genetics interact to impact how active tuberculosis presents clinically. We determined the phylogenetic lineages of M. tuberculosis isolates from participants enrolled in the Tuberculosis Trials Consortium Study 28, conducted in Brazil, Canada, South Africa, Spain, Uganda and the United States, and secondarily explored the relationship between lineage, clinical presentation and response to treatment. Large sequence polymorphisms and single nucleotide polymorphisms were analyzed to determine lineage and sublineage of isolates. Of 306 isolates genotyped, 246 (80.4%) belonged to the Euro-American lineage, with sublineage 724 predominating at African sites (99/192, 51.5%), and the Euro-American strains other than 724 predominating at non-African sites (89/114, 78.1%). Uneven distribution of lineages across regions limited our ability to discern significant associations, nonetheless, in univariate analyses, Euro-American sublineage 724 was associated with more severe disease at baseline, and along with the East Asian lineage was associated with lower bacteriologic conversion after 8 weeks of treatment. Disease presentation and response to drug treatment varied by lineage, but these associations were no longer statistically significant after adjustment for other variables associated with week-8 culture status.

Influence of transport and time on blood variables commonly measured for the athlete biological passport.

Some recent studies have characterized the stability of blood variables commonly measured for the Athlete Biological Passport. The aim of this study was to characterize the impact of different shipments conditions and the quality of the results returned by the haematological analyzer. Twenty-two healthy male subjects provided five EDTA tubes each. Four shipment conditions (24, 36, 48, 72 h) under refrigerated conditions were tested and compared to a set of samples left in the laboratory also under refrigerated conditions (group control). All measurements were conducted using two Sysmex XT-2000i analyzers. Haemoglobin concentration, reticulocytes percentage, and OFF-score numerical data were the same for samples analyzed just after collection and after a shipment under refrigerated conditions up to 72 h. Detailed information reported especially by the differential (DIFF) channel scatterplot of the Sysmex XT-2000i indicated that there were signs of blood deterioration, but were not of relevance for the variables used in the Athlete Biological Passport. As long as the cold chain is guaranteed, the time delay between the collection and the analyses of blood variables can be extended. Copyright© 2015 John Wiley & Sons, Ltd.

Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism.

Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism. Azorin JM, Bowden CL, Garay RP, Perugi G, Vieta E, Young AH. Source Department of Psychiatry, CHU Sainte Marguerite, Marseilles, France. Abstract About half of all bipolar patients have an alcohol abuse problem at some point of their lifetime. However, only one randomized, controlled trial of pharmacotherapy (valproate) in this patient population was published as of 2006. Therefore, we reviewed clinical trials in this indication of the last four years (using mood stabilizers, atypical antipsychotics, and other drugs). Priority was given to randomized trials, comparing drugs with placebo or active comparator. Published studies were found through systematic database search (PubMed, Scirus, EMBASE, Cochrane Library, Science Direct). In these last four years, the only randomized, clinically relevant study in bipolar patients with comorbid alcoholism is that of Brown and colleagues (2008) showing that quetiapine therapy decreased depressive symptoms in the early weeks of use, without modifying alcohol use. Several other open-label trials have been generally positive and support the efficacy and tolerability of agents from different classes in this patient population. Valproate efficacy to reduce excessive alcohol consumption in bipolar patients was confirmed and new controlled studies revealed its therapeutic benefit to prevent relapse in newly abstinent alcoholics and to improve alcohol hallucinosis. Topiramate deserves to be investigated in bipolar patients with comorbid alcoholism since this compound effectively improves physical health and quality of life of alcohol-dependent individuals. In conclusion, randomized, controlled research is still needed to provide guidelines for possible use of valproate and other agents in patients with a dual diagnosis of bipolar disorder and substance abuse or dependence.

El secret del càncer més resistent

En la lluita contra el càncer, la recerca de nous fàrmacs cada cop més efectius i específics sovint troba un escull important: en molts tumors hi ha una petita fracció de cèl·lules resistents, que no es poden eliminar fàcilment. Tanmateix, el principal problema no és aquest, sinó que, a més, acostumen a respondre als fàrmacs incrementant la taxa de proliferació i la capacitat de fer metàstasi. Això fa que alguns tractaments no acabin de ser del tot efectius a llarg termini, per la presència cada cop més nombrosa i dispersa d'aquestes cèl·lules canceroses resistents. L'equip de recerca de Joan Massagué, al Memorial Sloan Kettering Cancer Center de Nova York, ha demostrat que aquest efecte a llarg termini induït pels mateixos fàrmacs és perquè les cèl·lules sensibles, abans de morir, preparen un ambient molt favorable per a les resistents.

The use of non-human primates as animal models for the study of hepatitis viruses

Hepatitis viruses belong to different families and have in common a striking hepatotropism and restrictions for propagation in cell culture. The transmissibility of hepatitis is in great part limited to non-human primates. Enterically transmitted hepatitis viruses (hepatitis A virus and hepatitis E virus) can induce hepatitis in a number of Old World and New World monkey species, while the host range of non-human primates susceptible to hepatitis viruses transmitted by the parenteral route (hepatitis B virus, hepatitis C virus and hepatitis delta virus) is restricted to few species of Old World monkeys, especially the chimpanzee. Experimental studies on non-human primates have provided an invaluable source of information regarding the biology and pathogenesis of these viruses, and represent a still indispensable tool for vaccine and drug testing.

The effect of 17-B estradiol therapy on bone mineral density and structure of alveolar bone in the ovariectomized rat model of postmenopausal osteoporosis

The ovariectomized (OVX) rat, a preclinical model for studying postmenopausal bone loss, may also be used to study differences in alveolar bone (AB). The objectives of this study were to quantify the differences in AB following estrogen replacement therapy (ERT), and to investigate the relationship between AB structure and density, and trabecular bone at the femoral neck (FN) and third lumbar vertebral body (LB3). Estrogen treated rats had a higher bone volume fraction (BV/TV) at the AB region (9.8% P < 0.0001), FN (12% P < 0.0001), and LB3 (11.5% P < 0.0001) compared to the OVX group. BV/TV of the AB was positively correlated with the BV/TV at the FN (r = 0.69 P < 0.0001) and the LB3 (r = 0.75 P < 0.0001). The trabecular number (Tb.N), trabecular separation (Tb.Sp), and structure model index (SMI) were also positively correlated (P < 0.05) between the AB and FN (r = 0.42, 0.49, and 0.73, respectfully) and between the AB and LB3 (r = 0.44, 0.63, and 0.69, respectfully). Given the capacity of AB to respond to ERT, future preclinical drug/nutritional intervention studies aimed at improving skeletal health should include the AB as a region of interest (ROI).

Caractérisation d'un modèle animal de douleur articulaire associée à l'arthrose du genou chez le rat Sprague-Dawley

La douleur articulaire associée à l’arthrose est un problème clinique majeur, spécialement chez les personnes âgées. L’intensité de la douleur est souvent amplifiée lors de mouvement de l’articulation et principalement lors du soutien de la charge corporelle sur le membre lésé. Malheureusement, les traitements pharmacologiques proposés sont trop souvent associés à des effets secondaires néfastes et à une inefficacité pour le soulagement de la douleur à long terme. Divers modèles murins sont utilisés en laboratoire de recherche pour des études précliniques de molécules aux propriétés analgésiques. Une évaluation comparative de la réponse comportementale douloureuse des animaux d’un modèle d’instabilité articulaire induit par le sectionnement du ligament croisé antérieur accompagné d’une méniscectomie partielle (le modèle ACLT+pMMx) et d’un modèle de dégénérescence articulaire induite par le monoiodoacetate (le modèle MIA) a permis de sélectionner un modèle approprié pour la continuité du projet. Les deux modèles ont démontré des lésions tissulaires, mais le modèle MIA a démontré une réponse douloureuse plus prononcée que le modèle ACLT+pMMx. Par l’analyse de la démarche, le modèle MIA a démontré une boiterie claire dans le patron de la démarche des animaux qui est associée à une lésion unilatérale. Le modèle MIA a donc été choisi pour la suite du projet. La problématique principale dans la recherche sur la douleur associée à l’arthrose est une compréhension incomplète des mécanismes de douleur responsables de l’induction et du maintien de l’état de douleur. Il devient donc nécessaire d’améliorer nos connaissances de ces mécanismes en effectuant une caractérisation plus approfondie des modèles animaux employés pour l’évaluation de stratégies pharmacologiques analgésiantes. Afin de bien comprendre le modèle MIA, une caractérisation des événements moléculaires centraux lors de la progression du processus dégénératif des structures articulaires de ce modèle s’est effectuée aux jours 3, 7, 14, 21 et 28 post injection. Des mécanismes hétérogènes qui modulent l’information nociceptive en fonction de la progression temporelle de la pathologie ont été observés. Les changements du contenu i spinal des neuropeptides sélectionnés (substance P, CGRP, dynorphine A et Big dynorphine) ont débuté sept jours suivant l’injection de MIA. L’observation histologique a démontré que les dommages structuraux les plus importants surviennent entre les jours 14 et 21. C’est entre les jours 7 et 21 que les lésions démontrent le plus de similarités à la pathologie humaine. Cela suggère que lors d’une évaluation préclinique d’un traitement pharmacologique pour pallier la douleur articulaire utilisant le modèle MIA, l’étude doit tenir compte de ces événements afin de maximiser l’évaluation de son efficacité. Puisque les traitements pharmacologiques conventionnels proposés pour le soulagement de la douleur ne font pas l’unanimité en terme d’efficacité, d’effets non désirés et de coûts monétaires parfois onéreux, les molécules de dérivés de plante deviennent une alternative intéressante. L’eugénol, le principal constituant de l’huile de clou de girofle, a été administré oralement pour une période de 28 jours chez des rats ayant reçu l’injection intra-articulaire de MIA afin d’évaluer son efficacité pour le traitement de la douleur articulaire. L’eugénol à une dose de 40 mg/kg s’est révélé efficace pour l’amélioration du patron de la démarche des animaux ainsi que pour la diminution de l’allodynie mécanique secondaire. De plus, les concentrations spinales de neuropeptides pronocicepteurs ont diminué chez les animaux traités. Par une évaluation histopathologique, l’eugénol n’a démontré aucune évidence d’effets toxiques suite à une administration per os quotidienne pour une période prolongée. Ces résultats suggèrent le potentiel thérapeutique complémentaire de la molécule d’eugénol pour le traitement de la douleur articulaire.

La protection des données de santé des athlètes dans le cadre de la lutte contre le dopage

Le dopage fait l’objet d’une intense lutte par les autorités sportives. Cet article s’intéresse à l’encadrement des renseignements personnels des athlètes qui y sont soumis. En effet, la lutte au dopage s’opère principalement par le traitement des nombreuses informations de santé que les athlètes fournissent dans le cadre de certaines procédures. L’article étudie dans une première partie les fondements de la lutte antidopage et la structure du sport aux niveaux international et canadien dans le but de contextualiser l’analyse de la protection des renseignements personnels. La seconde partie porte dans un premier temps sur le cadre général de la protection des renseignements personnels, puis sur les deux « outils » de la lutte au dopage : les autorisations pour usage à des fins thérapeutiques et les contrôles antidopage. Dans le premier cas, la protection des renseignements personnels s’effectue selon le modèle des aires de partage, où plusieurs personnes ont un accès simultané aux renseignements afin de fournir une prestation donnée. Dans le second cas, la protection est plus classique mais a la particularité de se confondre partiellement avec les mesures visant à protéger l’intégrité ­ et la validité ­ des contrôles.

Treatment of fibrinolytic alveolitis with rifamycin B diethylamide associated with gelfoam: a histological study.

The most common complication in the healing of extraction wounds is fibrinolytic alveolitis, which may also be termed dry socket. Reduction in the incidence of this condition after the application of topical antibiotics and the use of systemic antibiotics has been reported. A histological study of disturbed alveolar socket healing in rats was carried out to analyze the influence of application of rifamycin B diethylamide (Rifocin M) associated or not with Gelfoam. Sixty-four male rats (Rattus norvegicus albinus, Wistar), weighing 120-150 g, were divided into 4 groups of 16 animals each. In the second group of rats which received implants of Gelfoam, there was an intense resorption of bone walls in the initial stage. The rats that received implants of Gelfoam saturated with Rifocin M (fourth group) showed better results than the second group. The third group (only irrigation with rifamycin) showed better bone formation in the alveolar socket compared to the first, second and fourth groups. Thus, these results showed that rifamycin irrigation is useful in the control of alveolar infections.

Droga, alcol e lavoro: La prevenzione come promozione della salute

Lo scopo di questa dissertazione è quello di costruire un modello di promozione della salute nel contesto di lavoro in relazione al consumo di sostanze psicoattive fra lavoratori, attraverso il confronto tra la situazione italiana e inglese. L’ipotesi di fondo rimanda all’idea che i luoghi di lavoro possano rappresentare setting d’elezione per i progetti di prevenzione non solo perché alcuni studi dimostrano l’esistenza di fattori di rischio connessi alla mansione rispetto alle condotte relative allo stile di vita, ma anche perché il consumo di alcol e droghe è altamente diffuso tra i lavoratori e questo comporta rischi per la sicurezza e la salute personale nonché quella dei colleghi di lavoro. Si tratta quindi di indagare il rapporto tra contesto lavorativo e utilizzo di sostanze al fine di suggerire  alla luce degli studi internazionali in materia e delle riflessioni condotte dai soggetti coinvolti nella ricerca che si andrà a presentare  linee guida e indicazioni operative per la realizzazione di interventi di promozione alla salute nei contesti professionali. A tal fine, saranno analizzati gli esiti di 13 focus group che hanno coinvolto esperti italiani e 6 interviste somministrate a esperti inglesi volti a definire la situazione attuale in Italia e Gran Bretagna in materia di prevenzione del consumo di alcol e droghe nei luoghi di lavoro. In particolare, l’analisi verterà sulle seguenti aree: - Percezione circa la diffusione dei consumi nei luoghi di lavoro - Presentazione delle politiche adottate, in logica comparativa, tra i due paesi. - Analisi critica degli interventi e problematiche aperte. L’analisi del materiale empirico permette di delineare due modelli costruiti sulla base dei focus group e delle interviste: - in Italia si può affermare che prevalga il cd. modello della sicurezza: di recente trasformazione, questo sistema enfatizza la dimensione del controllo, tanto che si parla di sorveglianza sanitaria. É orientato alla sicurezza concepita quale rimozione dei fattori di rischio. Il consumo di sostanze (anche sporadico) è inteso quale espressione di una patologia che richiede l’intervento sanitario secondo modalità previste dal quadro normativo: una procedura che annulla la discrezionalità sia del datore di lavoro sia del medico competente. Si connota inoltre per contraddizioni interne e trasversali rispetto alle categorie lavorative (i controlli non si applicano alle professioni associate a maggiore prestigio sociale sebbene palesemente associate a rischio, come per esempio i medici) e alle sostanze (atteggiamento repressivo soprattutto verso le droghe illegali); - in Gran Bretagna, invece, il modello si configura come responsabilità bilaterale: secondo questo modello, se è vero che il datore di lavoro può decidere in merito all’attuazione di misure preventive in materia di alcol e droghe nei luoghi di lavoro, egli è ritenuto responsabile della mancata vigilanza. D’altro canto, il lavoratore che non rispetta quanto previsto nella politica scritta può essere soggetto a licenziamento per motivi disciplinari. Questo modello, particolarmente attento al consumo di tutte le sostanze psicoattive (legali e illegali), considera il consumo quale esito di una libera scelta individuale attraverso la quale il lavoratore decide di consumare alcol e droghe così come decide di dedicarsi ad altre condotte a rischio. Si propone di ri-orientare le strategie analizzate nei due paesi europei presi in esame attraverso la realizzazione di un modello della promozione della salute fondato su alcuni punti chiave: – coinvolgimento di tutti i lavoratori (e non solo coloro che svolgono mansioni a rischio per la sicurezza) al fine di promuovere benessere secondo un approccio olistico di salute, orientato ad intervenire non soltanto in materia di consumo di sostanze psicoattive (legali e illegali), ma più in generale sulle condotte a rischio; – compartecipazione nelle diverse fasi (programmazione, realizzazione e valutazione del progetto) del lavoratore, datore di lavoro e medico competente secondo una logica di flessibilità, responsabilizzazione condivisa fra i diversi attori, personalizzazione e co-gestione dell’intervento; – azione volta a promuovere i fattori di protezione agendo simultaneamente sul contrasto dei fattori di rischio (stress, alienazione, scarso riconoscimento del ruolo svolto), attraverso interventi che integrano diverse strategie operative alla luce delle evidenze scientifiche (Evidence-Based Prevention); – ricorso a strumenti di controllo (drug testing) subordinato all’esigenza di tutelare l’incolumità fisica del lavoratore e dei colleghi, da attuarsi sempre e comunque attraverso prassi che non violino la privacy e attraverso strumenti in grado di verificare l’effettivo stato di alterazione psico-fisica sul luogo di lavoro; – demedicalizzazione delle situazioni di consumo che non richiedono un intervento prettamente sanitario, ma che al contrario potrebbero essere affrontate attraverso azioni incentrate sul care anziché la cure; – messa a disposizione di servizi ad hoc con funzione di supporto, counselling, orientamento per i lavoratori, non stigmatizzanti e con operatori di formazione non solamente sanitaria, sull’esempio degli EAPs (Employee Assistence Programs) statunitensi. Si ritiene che questo modello possa trasformare i contesti di lavoro da agenzie di controllo orientate alla sicurezza a luoghi di intervento orientati al benessere attraverso un’azione sinergica e congiunta volta a promuovere i fattori di protezione a discapito di quelli di rischio in modo tale da intervenire non soltanto sul consumo di sostanze psicotrope, ma più in generale sullo stile di vita che influenza la salute complessiva.

Detection and identification of 700 drugs by multi-target screening with a 3200 Q TRAP LC-MS/MS system and library searching

The multi-target screening method described in this work allows the simultaneous detection and identification of 700 drugs and metabolites in biological fluids using a hybrid triple-quadrupole linear ion trap mass spectrometer in a single analytical run. After standardization of the method, the retention times of 700 compounds were determined and transitions for each compound were selected by a "scheduled" survey MRM scan, followed by an information-dependent acquisition using the sensitive enhanced product ion scan of a Q TRAP hybrid instrument. The identification of the compounds in the samples analyzed was accomplished by searching the tandem mass spectrometry (MS/MS) spectra against the library we developed, which contains electrospray ionization-MS/MS spectra of over 1,250 compounds. The multi-target screening method together with the library was included in a software program for routine screening and quantitation to achieve automated acquisition and library searching. With the help of this software application, the time for evaluation and interpretation of the results could be drastically reduced. This new multi-target screening method has been successfully applied for the analysis of postmortem and traffic offense samples as well as proficiency testing, and complements screening with immunoassays, gas chromatography-mass spectrometry, and liquid chromatography-diode-array detection. Other possible applications are analysis in clinical toxicology (for intoxication cases), in psychiatry (antidepressants and other psychoactive drugs), and in forensic toxicology (drugs and driving, workplace drug testing, oral fluid analysis, drug-facilitated sexual assault).

In vitro differentiation of near-unlimited numbers of functional mouse basophils using conditional Hoxb8

Background: Basophils constitute a rare leukocyte population known for their effector functions in inflammation and allergy, as well as more recently described immunoregulatory roles. Besides their low frequency, functional analysis of basophils is hindered by a short life span, inefficient ex vivo differentiation protocols, and lack of suitable cell models. A method to produce large quantities of basophils in vitro would facilitate basophil research and constitute a sought-after tool for diagnostic and drug testing purposes. Methods: A method is described to massively expand bone marrow–derived basophils in vitro. Myeloid progenitors are conditionally immortalized using Hoxb8 in the presence of interleukin-3 (IL-3) and outgrowing cell lines selected for their potential to differentiate into basophils upon shutdown of Hoxb8 expression. Results: IL-3-dependent, conditional Hoxb8-immortalized progenitor cell lines can be expanded and maintained in culture for prolonged periods. Upon shutdown of Hoxb8 expression, near-unlimited numbers of mature functional basophils can be differentiated in vitro within six days. The cells are end-differentiated and short-lived and express basophil-specific surface markers and proteases. Upon IgE- as well as C5a-mediated activation, differentiated basophils release granule enzymes and histamine and secrete Th2-type cytokines (IL-4, IL-13) and leukotriene C4. IL-3-deprivation induces apoptosis correlating with upregulation of the BH3-only proteins BCL-2-interacting mediator of cell death (BIM) and p53 upregulated modulator of apoptosis (PUMA) and downregulation of proviral integration site for Moloney murine leukemia virus 1 kinase (PIM-1). Conclusion: A novel method is presented to generate quantitative amounts of mouse basophils in vitro, which moreover allows genetic manipulation of conditionally immortalized progenitors. This approach may represent a useful alternative method to isolating primary basophils.